Literature DB >> 11356441

Effect of highly active antiretroviral therapy on frequency of oral warts.

D Greenspan1, A J Canchola, L A MacPhail, B Cheikh, J S Greenspan.   

Abstract

To investigate changes in the pattern of oral disease associated with highly active antiretroviral therapy (HAART), we assessed the frequency of these lesions in our clinic over 9 years. We retrospectively studied 1280 patients seen between July, 1990, and June, 1999, and related oral findings to medication use, immune function, and viral load. We found significant decreases in oral candidosis, hairy leucoplakia, and Kaposi's sarcoma over time, but no change in the occurrence of aphthous ulcers. There was an increase in salivary-gland disease and a striking increase in warts: three-fold for patients on antiretroviral therapy and six-fold for those on HAART (p=0.01). This pattern of oral disease in a referral clinic suggests that an increase in oral warts could be occurring as a complication of HAART.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356441     DOI: 10.1016/S0140-6736(00)04578-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  53 in total

1.  The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium.

Authors:  M Israr; D Mitchell; S Alam; D Dinello; J J Kishel; C Meyers
Journal:  HIV Med       Date:  2010-08-15       Impact factor: 3.180

2.  Effect of the HIV nucleoside reverse transcriptase inhibitor zidovudine on the growth and differentiation of primary gingival epithelium.

Authors:  D Mitchell; M Israr; S Alam; J Kishel; D Dinello; C Meyers
Journal:  HIV Med       Date:  2012-01-26       Impact factor: 3.180

3.  Orofacial manifestations in HIV positive children attending Mildmay Clinic in Uganda.

Authors:  Juliet Nabbanja; Sheba Gitta; Stefan Peterson; Charles Mugisha Rwenyonyi
Journal:  Odontology       Date:  2012-02-24       Impact factor: 2.634

4.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

5.  Proteomic and bioinformatic profile of primary human oral epithelial cells.

Authors:  Santosh K Ghosh; Elizabeth Yohannes; Gurkan Bebek; Aaron Weinberg; Bin Jiang; Belinda Willard; Mark R Chance; Michael T Kinter; Thomas S McCormick
Journal:  J Proteome Res       Date:  2012-10-16       Impact factor: 4.466

6.  HIV nucleoside reverse transcriptase inhibitors efavirenz and tenofovir change the growth and differentiation of primary gingival epithelium.

Authors:  D Mitchell; M Israr; S Alam; D Dinello; J Kishel; R Jia; C Meyers
Journal:  HIV Med       Date:  2013-10-31       Impact factor: 3.180

7.  Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals.

Authors:  Jennifer E Cameron; Isaac V Snowhite; Anil K Chaturvedi; Michael E Hagensee
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

8.  Highly tissue substructure-specific effects of human papilloma virus in mucosa of HIV-infected patients revealed by laser-dissection microscopy-assisted gene expression profiling.

Authors:  Nicole Baumgarth; Richard Szubin; Greg M Dolganov; Mitchell R Watnik; Deborah Greenspan; Maria Da Costa; Joel M Palefsky; Richard Jordan; Mario Roederer; John S Greenspan
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

Review 9.  Oral complications of HIV disease.

Authors:  Jair C Leao; Camila M B Ribeiro; Alessandra A T Carvalho; Cristina Frezzini; Stephen Porter
Journal:  Clinics (Sao Paulo)       Date:  2009-05       Impact factor: 2.365

10.  Development and validation of a HPV-32 specific PCR assay.

Authors:  Nicholas R Herrel; Nadia L Johnson; Jennifer E Cameron; Janet Leigh; Michael E Hagensee
Journal:  Virol J       Date:  2009-06-27       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.